NanoSyrinx
NanoSyrinx is an emerging biotechnology company developing a novel system for targeted delivery of therapeutic proteins and peptides direct to the cytosol. We are using synthetic biology approaches to develop a completely novel method for targeted drug delivery of therapeutic proteins and peptides, to the interiors of cells, to improve efficacy,safety, and economy.
NanoSyrinx has raised €19M across 2 funding rounds from 10 investors, most recently a round in Sep 2024. Based in Coventry, UK; active in Healthtech. Data as of 6 Aug 2026.
